首页> 外文期刊>Cell stress & chaperones >Rescuing of deficient killing and phagocytic activities of macrophages derived from non-obese diabetic mice by treatment with geldanamycin or heat shock: potential clinical implications
【24h】

Rescuing of deficient killing and phagocytic activities of macrophages derived from non-obese diabetic mice by treatment with geldanamycin or heat shock: potential clinical implications

机译:通过格尔德霉素或热休克治疗挽救非肥胖糖尿病小鼠巨噬细胞的杀伤和吞噬活性不足:潜在的临床意义

获取原文
           

摘要

Diabetes mellitus type 1 (DMT1) is an autoimmune disease characterized by the destruction of insulin-producing cells in the pancreas. Diabetic patients are more susceptible to recurrent and uncontrolled infections, with worse prognoses than in healthy individuals. Macrophages (M?s) derived from DMT1 individuals have compromised mounting of inflammatory and immune responses. The mechanisms responsible for these alterations remain unknown. It has been shown that the presence of extra- and intracellular heat shock proteins (hsp) positively modulates immune cell function. Using naive M?s derived from non-obese diabetic (NOD) mice, a well-established mouse model for DMT1, we demonstrate that heat shock (HS) as well as treatment with geldanamycin (GA), significantly improves diabetic M? activation, resulting in increased phagocytosis and killing of bacteria. Induction of HS did not affect the aberrant NOD-M? cytokine profile, which is characterized by elevated IL-10 levels and normal tumor necrosis factor alpha. Our observations were consistent at pre-diabetic (normal random blood glucose) and diabetic (random blood glucose greater than 250?mg/dl) stages, suggesting that HS and GA treatment may compensate for intrinsic genetic alterations present in diabetic cells regardless of the stage of the disease. The mechanisms associated to this phenomenon are unknown, but they may likely be associated with the induction of hsp expression, a common factor between HS and GA treatment. Our results may open a new field for non-classical function of hsp and indicate that hsp expression may be used as a part of therapeutic approaches for the treatment of complications associated with DMT1 as well as other autoimmune diseases.
机译:1型糖尿病(DMT1)是一种自身免疫性疾病,其特征是破坏了胰腺中产生胰岛素的细胞。糖尿病患者比健康个体更容易复发和不受控制的感染,预后更差。源自DMT1个体的巨噬细胞(M?s)损害了炎症和免疫反应的水平。造成这些改变的机制仍然未知。已经显示,细胞外和细胞内热休克蛋白(hsp)的存在正调节免疫细胞功能。使用源自非肥胖型糖尿病(NOD)小鼠的天真M?s(一种成熟的DMT1小鼠模型),我们证明了热休克(HS)以及格尔德霉素(GA)的治疗显着改善了糖尿病M?激活,导致吞噬作用增加和细菌杀死。诱导HS不会影响异常的NOD-M吗?细胞因子谱,其特征在于IL-10水平升高和正常的肿瘤坏死因子α。我们的观察在糖尿病前期(正常随机血糖)和糖尿病期(随机血糖大于250?mg / dl)阶段是一致的,这表明HS和GA治疗可能补偿了糖尿病细胞的固有遗传改变,无论其阶段如何这种疾病。与此现象相关的机制尚不清楚,但可能与hsp表达的诱导有关,hsp表达是HS和GA治疗之间的共同因素。我们的结果可能为hsp的非经典功能开辟了一个新领域,并表明hsp表达可用作治疗与DMT1以及其他自身免疫性疾病相关的并发症的治疗方法的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号